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Research Objectives
• To synthesize a 1,2,4-oxadiazolidinone derivatives via 1,3-
dipolar cycloaddition of nitrones with substituted 
isocyanates.
• To evaluate the biological significance of the synthesized 
inhibitors.
• To improve or restore the potency of antibiotic agents that 
lost their effectiveness due to continuous evolution of 
bacteria's β-lactamases.
Bacterial cell wall
Figure 1: A section of Gram-negative and Gram-positive cell wall
β-lactam antibiotic drugs
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Figure 2: Some β-lactam Antibiotics
Bacteria’ β-lactamases
Figure 3: Mechanism of resistance to antibiotics.
Justification of 1,2,4-oxadiazolidin-5-one
Figure 4: Comparison of compound of interest with Avibactam and linezolid
https://pubchem.ncbi.nlm.nih.gov/compound/9835049
www.idstewardship.com/drugs/ceftazidime-avibactam
http://www.avalonpharmacy.com/product/zyvox-linezolid/
Synthesis of nitrones
Scheme 1: Reaction of nitro compounds with benzaldehyde.
Ritter, T., Carreira, E. M. Angew. Chem., Int. Ed. 2005, 44 (6), 936-938
NO2
O
H H
N
NH4Cl, Zn, EtOH/H2O
0 C, rt, 24h
1a
o
NO2
O
H
95% EtOH, Acetic acid, Zn
0 C, rt, 24 h
1b
o
O
H
N
O
1,3-dipolar cycloaddition reaction
Scheme 2: Reaction of nitrones with various isocyanates
DOI: 10.1002/anie.200461934
CHARACTERIZATION AND BIOLOGICAL 
ACTIVITIES
Figure 5: 1H & 13C NMR spectra of Nitrone 1a
Figure 6: 1H & 13C NMR spectra of oxadiazolidinone 2a
Figure 7: 1H & 13C NMR spectra of compound 2c
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Figure 8: GC-MS spectrum of compound 2c
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Figure 9: IR spectra of compound 2c
Demonstration of cycloaddition
Figure 10: 1H NMR spectra of 1a and corresponding oxadiazolidinone 2a
Table 1: The cytotoxicity essay (%) of 2a on relative control (100%) against IGROV1, OVCAR-4, HS 578T, 
BT-549, A498, UO-31, UACC-62, SK-MEL-28
Cancer types Cell line Growth % % Inhibition
Ovarian Cancer IGROV1 95.59 4.41
OVCAR-4 95.84 4.16
Breast Cancer HS 578T 93.06 6.94
BT-549 99.50 0.50
Renal Cancer A498 82.27 17.73
UO-31 86.72 13.33
Melanoma UACC-62 93.93 6.07
SK-MEL-28 99.89 0.11
Final concentration & volume of Enzyme (TEM-1) = 3 µL (0.45 nM),
Substrate (NCF) = 12 uL (100 µM)
0.1 % BSA in MOPS buffer = 562 µL (0.02 mM, pH – 7.5)
Inhibitor (in 3 %ACN) = 20 µL (500 µM)
Enzyme Inhibition Kinetics
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Table 2: Residual Activity and Percent Inhibition of TEM-1 for 3 minutes, 30°C 
Utilizing Potential Synthesized Inhibitors*
Compound Molecular 
Weight 
(g/mol)
Initial Rate
V˳ ± SD (ΔA, sec-1) 
× 10-3
Initial Rate 
+Inhibitor
Vi ± SD (ΔA, 
sec-1) × 10-3
Residual 
Activity 
(%)
%
Inhibition
2a 268.31 1.6870 ± 0.01531 1.2930 ±
0.03163
76.47 23.53
2b 254.28 2.9367 ± 0.26697 2.1840 ±
0.34975
74.37 25.63
2C 280.00 1.159 ± 0.01139 1.0139 ±
0.02758
87.48 12.52
3 252.29 2.0411 ± 0.01252 1.2465 ±
0.01698
61.07 38.93
3 (P99) 252.29 7.1434 ± 0.15520 5.5067 ±
0.15981
77.09 22.91
Conclusion
• In this work, oxadiazolidinone derivatives (2a, 2b, 2c, and 3), were 
prepared using commercially available isocyanate derivatives with 
synthesized nitrone 1a and 1b.The synthesized inhibitors were characterized 
using 1H and 13C NMR, GC-MS, and IR.
• Afterwards, there were tested against TEM-1 and P99 serine β-lactamase. 
Compound 2a, 2b, 2c, and 3 showed inhibition ranging from 12-38%  and 3
showed 22% inhibition against P99
• MTT Essay was used to test the in vitro cytotoxicity of oxadiazolidinone 
2a on cancer cell lines. 2a had more activity on renal cancer, decreasing the 
cell viability of 786-0 by about 18%. The activity on other cell lines ranged 
from 4-14%.
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